883 N. Shoreline Blvd., Suite A100
Tel: (650) 382-2605
30 articles about Aria Pharmaceuticals
Aria Pharmaceuticals Presents Positive In Vivo Data on Lead Idiopathic Pulmonary Fibrosis Treatment Candidate
Aria Pharmaceuticals, a pharmaceutical company focused on bringing first-in-class small molecules to market, today announced that its lead candidate for idiopathic pulmonary fibrosis (IPF), TXR-1002, demonstrated significant efficacy in new preclinical research.
Aria Pharmaceuticals secured six provisional patents to cover the lead drug candidates for its lupus, idiopathic pulmonary fibrosis and chronic kidney disease research programs.
Aria Pharmaceuticals announced that the company has successfully filed a total of six provisional patents with the United States Patent and Trademark Office (USPTO) for lead candidates in its lupus, idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD) research programs.
Aria Pharmaceuticals is using a unique computational approach to drug development that has increased its success rate by 30-fold when compared to traditional approaches.
Aria Pharmaceuticals Presents Positive In Vivo Data Showing Two Novel Treatment Candidates Demonstrated Positive Efficacy and Tolerability in Idiopathic Pulmonary Fibrosis Compared to Standard of Care
Aria Pharmaceuticals, a drug discovery and development company focused on bringing first-in-class small molecules to market, today announced that two novel candidates for the potential treatment of idiopathic pulmonary fibrosis (IPF), TXR-1002 and TXR-1007, demonstrated significant efficacy and excellent tolerability in preclinical studies.
twoXAR Pharmaceuticals Rebrands as Aria Pharmaceuticals, Provides Pipeline Update and Announces New Therapeutic Development Strategy
twoXAR, Inc., a Delaware corporation focused on discovering and bringing first-in-class small molecules to market, today announced that the company will rebrand as Aria Pharmaceuticals.
twoXAR Pharmaceuticals Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311
TXR-311 was identified, screened and selected as an in vivo candidate and demonstrated efficacy comparable to sorafenib with good tolerability
Rosen is a Veteran Pharmaceutical Leader and has Held Senior Positions at Some of the World's Top Pharmaceutical Companies
1ST Biotherapeutics and twoXAR Advance Three Novel Glioblastoma Treatment Candidates into In Vivo Testing in Less Than One Year
Partnership Combines Shared Drug Discovery Expertise with Integrated Artificial Intelligence to Identify Promising Targets in Half the Time of Traditional R&D Approaches
9/20/2019Biotech and pharma companies from across the globe strengthen their leadership teams and boards of directors with this week's appointments.
twoXAR Announces Appointment of Allen Poirson, Ph.D. as Senior Vice President of Biopharmaceutical Business Development
twoXAR, Inc., an artificial intelligence-driven biopharmaceutical company, today announced the appointment of Allen Poirson, Ph.D. as the company’s Senior Vice President of Biopharmaceutical Business Developmen
SK Biopharmaceuticals and twoXAR Sign Collaboration Agreement to Discover and Develop First-In-Class Treatments for Non-Small Cell Lung Cancer
SK Biopharmaceuticals and twoXAR, Inc. announced an agreement to discover and develop first-in-class therapeutics for non-small cell lung cancer.
Ono Pharmaceutical Co., Ltd. announced that the companies have signed a drug discovery research collaboration to jointly discover and develop novel, efficacious treatments to address unmet medical needs in a specific neurological disease.
1ST Biotherapeutics and twoXAR Form Co-Development Collaboration to Discover and Develop Treatments for Glioblastoma
1ST Biotherapeutics, Inc. and twoXAR, Inc. today announced an agreement to jointly discover and develop novel, efficacious treatments to address unmet medical needs in glioblastoma multiforme (“glioblastoma”).
Identifying novel PDAC candidates using a computational approach
Drug Development Approach Combines twoXAR’s Artificial Intelligence-Driven Discovery Technology with the Adynxx Team’s Development Experience
twoXAR Inc. announced that it has raised $10 million in Series A financing led by SoftBank Ventures, a SoftBank Group early stage venture capital arm.
Industry veterans Judy Lewent, Jonathan MacQuitty, and Howie Rosen bring to twoXAR nearly 90 years of combined R&D and commercial experience in the biopharmaceutical sector.